DeCure for Arrhythmogenic right ventricular dysplasia, familial, 14
DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for arrhythmogenic right ventricular dysplasia, familial, 14 — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleArrhythmogenic right ventricular dysplasia, familial, 14 maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for arrhythmogenic right ventricular dysplasia, familial, 14 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Arrhythmogenic right ventricular dysplasia is a rare inherited disease characterised by right ventricular dysfunction and ventricular arrhythmias. Most forms result from mutations in genes encoding desmosomal junction proteins. Magnetic resonance imaging is a very sensitive tool but also the most common reason for overdiagnosis. In the USA, most patients who meet Task Force criteria undergo placement of an implantable cardioverter defibrillator for prevention of sudden cardiac death.
A 42 year old woman resuscitated from ventricular fibrillation had right precordial T wave inversion, inferior wall akinesia of the right ventricle with normal left ventricular function, and focal fibrous infiltration on endomyocardial biopsy. Ventricular fibrillation could not be reproduced by programmed stimulation. An implantable cardioverter defibrillator was implanted; within six months its memory showed no evidence of ventricular fibrillation. The authors note that concealed arrhythmogenesis as an early manifestation is difficult to detect.
An 87 year old female with no significant medical history is presented as an unusual case of ARVD. The abstract provides no further clinical details, no treatment, and no outcome data for this patient.
No drug treatment is mentioned in any of these abstracts. What is missing is any controlled trial of pharmacological therapy for this condition, any data on drug repurposing, and any stratification of patients by genotype or disease stage that might guide future treatment studies.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Cardiology · 2005 · 95 citations
AbstractPURPOSE OF REVIEW: Arrhythmogenic right-ventricular dysplasia is a rare inherited disease characterized by right-ventricular dysfunction and ventricular arrhythmias. The purpose of this article is to review recent developments concerning the diagnosis, genetics, and management of patients with this disease. RECENT FINDINGS: In the past few years important new information has emerged regarding the role of magnetic resonance imaging in the diagnosis of arrhythmogenic right-ventricular dysplasia. Although magnetic resonance imaging is a very sensitive tool, it is also the most common reason for over diagnosis of this condition. There have also been important new breakthroughs in the genetic basis of arrhythmogenic right-ventricular dysplasia; it now appears that most forms result from mutations in genes encoding desmosomal junction proteins. This may explain why arrhythmogenic right-ventricular dysplasia preferentially impacts the thin right ventricle. Other studies have demonstrated the important role of implantable cardioverter defibrillator therapy in the management of patients with arrhythmogenic right-ventricular dysplasia. In the USA, most patients who meet the Task Force criteria for the disease undergo placement of an implantable cardioverter defibrillator for prevention of sudden cardiac death. SUMMARY: Arrhythmogenic right-ventricular dysplasia is a rare disease. Recent new findings concerning the diagnosis and management of these patients should have direct implications regarding the evaluation and management of patients with this rare, but potentially life-threatening, disorder.
DMW - Deutsche Medizinische Wochenschrift · 2003 · 0 citations
Arrhythmogene rechtsventrikuläre Dysplasie als Ursache eines überlebten plötzlichen Herztodes
AbstractHISTORY: A 42 year old woman was resuscitated from ventricular fibrillation. 5 months previously she had a syncope. Her nephew had died of sudden cardiac death at the age of 25 years. INVESTIGATIONS: There was no evidence for ST segment elevation, myocardial infarction or pulmonary embolism. The ECG showed right precordial T wave inversion. Coronary artery disease was excluded angiographically. Echocardiography and angiography revealed inferior wall akinesia of the right ventricle with normal left ventricular function and chamber size. Ventricular fibrillation could not be reproduced by programmed stimulation of the right ventricle during an electrophysiologic study. Results of endomyocardial biopsy of the right ventricle showed a focal fibrous infiltration of the myocardium. Magnetic resonance imaging confirmed inferior wall abnormalities of the right ventricle without typical fatty infiltration in the right ventricular myocardium. CLINICAL COURSE: The patient recovered rapidly without neurologic deficits. Arrhythmogenic right ventricular dysplasia was suspected, and a cardioverter defibrillator (ICD) was implanted. Within 6 months after implantation the ICD memory showed no evidence of ventricular fibrillation. CONCLUSION: Arrhythmogenic right ventricular dysplasia is an important cause of ventricular fibrillation with a potential risk of sudden cardiac death in young persons. Concealed arrhythmogenesis as an early manifestation of right ventricular dysplasia is difficult to detect.
Med Discoveries · 2024 · 0 citations · open access
Unusual Presentation of Arrhythmogenic Right Ventricular Dysplasia in an Elderly Patient
AbstractArrhythmogenic Right Ventricular Dysplasia (ARVD) is a genetic myocardial disorder characterized by progressive fibrofatty infiltration, predisposing to arrhythmias and sudden cardiac death, primarily affecting young individuals [1,2]. Here, we present the case of an 87-year-old female with no significant medical history
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
